The world’s largest clinical trial on cannabidiol (CBD) as a treatment for insomnia has been given the green light to complete its Phase III trial, transforming the fortunes of Avecho Biotechnology, and potentially the lives of insomnia sufferers worldwide.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug from Munich-based Vertanical, putting it in prime position to become the first FDA-approved cannabis-derived medicine for pain, and only the second such approval since Epidiolex in 2018.
In April 2025, the Italian government used emergency constitutional powers to bypass parliament and reclassify non-intoxicating hemp as a narcotic, regardless of THC content, following multiple failed attempts to decimate the industry.
US cannabis rescheduling is unlikely to trigger a land grab.
Curaleaf Laboratories, one of the UK-leading pharmaceutical-grade medical cannabis manufacturers, is delighted to announce a partnership with Berlin-based Sanity Group, a European life science company focused on cannabinoids and wellbeing products.
Today (February 19, 2026), Cannabis Europa returns to the French capital for the first time since 2019 at a critical juncture for the incoming French medical cannabis industry.
